1. Home
  2. CSTL vs UHT Comparison

CSTL vs UHT Comparison

Compare CSTL & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$34.49

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Logo Universal Health Realty Income Trust

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$39.05

Market Cap

561.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
UHT
Founded
2007
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
561.5M
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
CSTL
UHT
Price
$34.49
$39.05
Analyst Decision
Strong Buy
Hold
Analyst Count
6
1
Target Price
$45.50
$43.00
AVG Volume (30 Days)
275.5K
81.1K
Earning Date
05-06-2026
04-27-2026
Dividend Yield
N/A
7.33%
EPS Growth
N/A
N/A
EPS
N/A
0.79
Revenue
$344,229,000.00
$99,190,000.00
Revenue This Year
$2.42
$2.12
Revenue Next Year
$12.69
$2.94
P/E Ratio
N/A
$50.27
Revenue Growth
3.66
0.18
52 Week Low
$17.72
$35.26
52 Week High
$44.28
$46.30

Technical Indicators

Market Signals
Indicator
CSTL
UHT
Relative Strength Index (RSI) 58.21 32.64
Support Level $22.88 $38.11
Resistance Level $42.03 $42.79
Average True Range (ATR) 1.44 0.85
MACD 0.01 -0.13
Stochastic Oscillator 57.86 7.17

Price Performance

Historical Comparison
CSTL
UHT

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

Share on Social Networks: